

nView vs. PHQ-9

Your behavioral assessment tools may be putting your patients and your practice at risk.

#1

INDEPENDENCE MATTERS

nView screeners and interviews were independently developed by trained psychiatrists with no connections to drug manufacturers.

NOT BIG PHARMA

The PHQ-9 was built and owned by one of the drug manufacturers that offers the leading anti-depression medications.

#2

THE CLINICAL STANDARD

The PHQ-9 and other screeners attempt to validate against nView's screeners and interviews since they are viewed in the industry as the clinical standard of excellence.

CITED BY

20K+



regulatory and clinical studies, and clinically validated and peer reviewed.

MENTAL HEALTH GOES FAR BEYOND THE LAST 2 WEEKS

The PHQ-9 asks a patient to self-report over the last two weeks. This can lead to under-diagnosis or even worse – misdiagnosis – which can increase risk in some patients (ie. those with Impulse Attack Suicidality Disorder.)

65.9%

**MISDIAGNOSIS RATE
for Major Depressive
Disorder***

*National Institutes of Health Report (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184591>)

#3

ALL IN ONE

The PHQ-9 only screens for symptoms of depression – no matter what the cause. This leads to misdiagnosis of complete depressive disorders. nView solutions are comprehensive and screen for all major mental disorders in one solution.

19

Adult
Symptom
Complexes

25

Pediatric
Symptom
Complexes

#4

REIMBURSABLE

In addition to the M.I.N.I. structured interview, nView offers a full range of screeners, severity scales and monitors that are reimbursed by all of the major payers.

WIN-WIN

nView screeners and interviews are a must-have to improve the health of your patients and your practice.



Ready to take your practice into the next generation?

SPEAK WITH A CLINICAL EXPERT @ NVIEW.COM